Improving viral vector titer and impurity analyses with automated ELISA systems
Dec
13
2023
On demand

Improving viral vector titer and impurity analyses with automated ELISA systems

Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Improving viral vector titer and impurity analyses with automated ELISA systems

ELISA is considered the gold standard in analytics because it is incredibly versatile, highly sensitive and specific, and can be performed using standard laboratory equipment.

However, with all the manual steps involved, ELISA can be time consuming and labour intensive. In addition, as data volumes continue to grow exponentially, relying solely on manual analysis can become increasingly difficult and inefficient, slowing down the overall analysis process and limiting productivity. Automating the manual ELISA process streamlines workflows, increases accuracy, and saves valuable time and resources.

This webinar will discuss how to maintain the versatility of manual ELISA when moving to an automated immunoassay platform.

Case studies will be presented to illustrate how plate-based ELISA analysis of viral vector titers (AAV and lentivirus) and impurity analysis (HCP, endonuclease) can be accelerated.

Attend this webinar to discover:

  • Approaches to accelerate plate-based ELISA assays
  • Reagent-efficient assay alternatives for impurity data generation
  • How the use of open platforms can increase productivity in gene therapy development
  • Approaches for rapid data generation and long-term performance for unique assay conditions
Daniel Forsström
Daniel Forsström
R&D Application and Custom Service Manager at Gyros Protein Technologies
Daniel Forsström is R&D Application and Custom Service Manager at Gyros Protein Technologies. He leads the R&D Application and Custom service teams for Gyros Protein Technologies and is responsible for developing new assays, new products and custom assay solutions for the Gyrolab platform. With almost 15 years’ experience in various positions at different biotech companies, he has extensive experience in developing analytical assays for high throughput technologies used in preclinical and clinical drug development.